Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.

ABSTRACT:

Introduction

The optimal management for immune-related adverse events (irAEs) in patients who do not respond or become intolerant to steroids is unclear. Guidelines suggest additional immunosuppressants on the basis of case reports and expert opinion.

Methods

We evaluated patients with lung cancers at Memorial Sloan Kettering Cancer Center treated with immune checkpoint blockade from 2011 to 2020. Pharmacy records were queried to identify patients who received systemic steroids and an additional immunosuppressant (e.g., tumor necrosis factor-α inhibitor, mycophenolate mofetil). Patient records were manually reviewed to evaluate baseline characteristics, management, and outcomes.

Results

Among 2750 patients with lung cancers treated with immune checkpoint blockade, 51

SUBMITTER: Luo J 

PROVIDER: S-EPMC8464489 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature